Nektar Therapeutics Senior Notes, Noncurrent
Nektar Therapeutics (NKTR) had Senior Notes, Noncurrent of $0 as of 2019-12-31, per its 10-K filed 2020-02-28.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:SeniorLongTermNotes · last filed 2020-02-28
- 2019-12-31: Senior Notes, Noncurrent $0.00.
- 2019-09-30: Senior Notes, Noncurrent $248.26M.
- 2019-06-30: Senior Notes, Noncurrent $247.82M.
- 2019-03-31: Senior Notes, Noncurrent $247.39M.
| Period end | Senior Notes, Noncurrent | Senior Notes, Noncurrent as first filed |
|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-28 | |
| 2019-09-30 | $248.26M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $247.82M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $247.39M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $246.95M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $246.51M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $246.08M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $245.64M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $245.21M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $244.77M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $244.34M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $243.90M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $243.46M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $243.00M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $242.57M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $242.13M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $241.70M 10-K · filed 2017-03-01 | $242.12M 10-K · filed 2016-02-29 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $125.00M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $125.00M 10-Q · filed 2015-05-01 | |
| 2014-12-31 | $125.00M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $125.00M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $125.00M 10-Q · filed 2014-08-01 | |
| 2014-03-31 | $125.00M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $125.00M 10-K · filed 2015-02-26 | |
| 2013-09-30 | $125.00M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $125.00M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $125.00M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $125.00M 10-K · filed 2014-02-27 | |
| 2012-09-30 | $125.00M 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |